A molecular perspective for the use of type IV tyrosine kinase inhibitors as anticancer therapeutics

Rudradip Das received his B Pharm degree in pharmaceutical technology from West-Bengal University of Technology, Kolkata, India, in 2017. He received his MS (Pharm) degree in medicinal chemistry under the guidance of Prof. PV Bharatam from NIPER-Mohali in 2019. Currently, he is pursuing a PhD in medicinal chemistry from the National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, India, under the guidance of Dr Amit Shard. His current research interest focuses on the design, synthesis and evaluation of small organic compounds as potential agents against PKM2.

Asmita Choithramani received her B Pharm degree from Vivekanand Education Society’s College of Pharmacy, Chembur (East), Mumbai, in the academic year 2019. She is currently pursuing an MS (Pharm) in medicinal chemistry, under the guidance of Dr Amit Shard from NIPER-Ahmedabad. Her research area focuses extensively on design, synthesis, computational studies and biological evaluation of modulators targeting PKM2.

Amit Shard received his MS degree in pharmaceutical chemistry from SBS (PGI) Dehradun and his PhD from CSIR-Institute of Himalayan Bioresource Technology, Palampur, working under the direction of Prof. Arun K Sinha. After completing his doctoral work, he joined as faculty at the National Institute of Pharmaceutical Education and Research-Ahmedabad in 2014. His research interests include the development of novel antitumor PKM2 modulators and computer-aided drug design.

© 2021 Elsevier Ltd. All rights reserved.

留言 (0)

沒有登入
gif